OCGN News and Press, Ocugen, Inc. From 03/25/24

2024-03-25 06:09:00 ET 3 Future Penny Stocks Investing Trends to Consider in 2024 Penny stocks represent a unique segment of the market, offering high potential returns to investors willing to navigate its volatility. Trading penny stocks in 2024 requires an understanding of emerging tr...

2024-03-24 06:24:00 ET 3 Top Penny Stocks Trading Mistakes to Avoid in 2024 Trading penny stocks offers a unique opportunity for both new and seasoned investors to diversify their portfolios and potentially reap significant returns. However, the journey to successful penny stock investm...

2024-03-22 05:59:02 ET More on related stocks Reddit: A Robust Growth Prospect With Fuel Behind It FedEx Corporation (FDX) Q3 2024 Earnings Call Transcript NIKE, Inc. (NKE) Q3 2024 Earnings Call Transcript FedEx in charts: U.S. package volume slips from last ...

2024-03-21 22:02:00 ET Ocugen (NASDAQ: OCGN) stock price has done well in the past few months as investors remain optimistic about its product pipeline. It jumped to a high of $1.60 on Thursday, the highest point in more than 52 weeks. At its peak this week, the stock was up by more tha...

2024-03-21 14:40:56 ET More on Ocugen Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Seeking Alpha’s Quant Rating on Ocugen Historical earnings data for Ocugen Financial information for Ocugen Read the...

2024-03-21 13:01:56 ET Gainers: Kaival Brands Innovations Group ( KAVL ) +137% . Yield10 Bioscience YTEN +91% . Lufax Holding Ltd LU +38% . Cazoo Group Ltd CZOO +36% . Aemetis AMTX +32% . Monogram Orthopaedics MGRM +28% . Ocugen ( ...

2024-03-19 09:36:55 ET Summary Ocugen Inc. is a biotechnology company focused on gene and cell therapies and inhalable vaccine development. Their OCU400 program, targeting inherited eye diseases, is progressing to phase 3 clinical trials in 2024. The company's participation in...

Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...

2024-03-18 07:02:06 ET More on Ocugen Seeking Alpha’s Quant Rating on Ocugen Historical earnings data for Ocugen Financial information for Ocugen Read the full article on Seeking Alpha For further details see: Ocugen promotes Huma Qamar as ...

MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. ...